Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurizio Martelli

Showing results (1-10 of 200) with videos related to

Pageof 20
Sort By:
Critical Reviews in Oncology/Hematology|September 9, 2008
Primary mediastinal large B-cell lymphomaMaurizio Martelli, Andrés J M Ferreri, Peter Johnson
Expert Opinion on Investigational Drugs|June 16, 2021
Asciminib: an investigational agent for the treatment of chronic myeloid leukemiaMassimo Breccia, Gioia Colafigli, Emilia Scalzulli, et al.
Frontiers in Oncology|July 31, 2023
Editorial: HBV and lymphomaGiuseppe Gentile, Luca Arcaini, Guido Antonelli, et al.
The Lancet. Oncology|October 4, 2017
Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' replyAnnalisa Chiappella, Maurizio Martelli, Andrea Evangelista, et al.
Cancer Treatment Reviews|February 13, 2025
Primary mediastinal large B-cell Lymphoma: Biological features, clinical characteristics and current treatment strategiesLivia Donzelli, Alice Di Rocco, Luigi Petrucci, et al.
International Journal of Radiation Oncology, Biology, Physics|March 1, 2017
In Reply to Adams and KweeLuca Ceriani, Peter W M Johnson, Maurizio Martelli, et al.
International Journal of Hematology|August 5, 2022
Asciminib as a third line option in chronic myeloid leukemiaAlessandro Laganà, Emilia Scalzulli, Ida Carmosino, et al.
Current Cancer Drug Targets|June 15, 2022
Future Management of Chronic Myeloid Leukemia: From Dose Optimization to New AgentsMassimo Breccia, Emilia Scalzulli, Sara Pepe, et al.
Expert Review of Hematology|December 25, 2014
Primary mediastinal lymphoma: diagnosis and treatment optionsMaurizio Martelli, Alice Di Rocco, Eleonora Russo, et al.
Current Hematologic Malignancy Reports|October 20, 2022
CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New DirectionsEmilia Scalzulli, Ida Carmosino, Maria Laura Bisegna, et al.
Pageof 20

Showing results (1-10 of 200) with videos related to

Sort By:
Pageof 20
Critical Reviews in Oncology/Hematology|September 9, 2008
Primary mediastinal large B-cell lymphomaMaurizio Martelli, Andrés J M Ferreri, Peter Johnson
Expert Opinion on Investigational Drugs|June 16, 2021
Asciminib: an investigational agent for the treatment of chronic myeloid leukemiaMassimo Breccia, Gioia Colafigli, Emilia Scalzulli, et al.
Frontiers in Oncology|July 31, 2023
Editorial: HBV and lymphomaGiuseppe Gentile, Luca Arcaini, Guido Antonelli, et al.
The Lancet. Oncology|October 4, 2017
Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' replyAnnalisa Chiappella, Maurizio Martelli, Andrea Evangelista, et al.
Cancer Treatment Reviews|February 13, 2025
Primary mediastinal large B-cell Lymphoma: Biological features, clinical characteristics and current treatment strategiesLivia Donzelli, Alice Di Rocco, Luigi Petrucci, et al.
International Journal of Radiation Oncology, Biology, Physics|March 1, 2017
In Reply to Adams and KweeLuca Ceriani, Peter W M Johnson, Maurizio Martelli, et al.
International Journal of Hematology|August 5, 2022
Asciminib as a third line option in chronic myeloid leukemiaAlessandro Laganà, Emilia Scalzulli, Ida Carmosino, et al.
Current Cancer Drug Targets|June 15, 2022
Future Management of Chronic Myeloid Leukemia: From Dose Optimization to New AgentsMassimo Breccia, Emilia Scalzulli, Sara Pepe, et al.
Expert Review of Hematology|December 25, 2014
Primary mediastinal lymphoma: diagnosis and treatment optionsMaurizio Martelli, Alice Di Rocco, Eleonora Russo, et al.
Current Hematologic Malignancy Reports|October 20, 2022
CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New DirectionsEmilia Scalzulli, Ida Carmosino, Maria Laura Bisegna, et al.
Pageof 20